Jennifer Fitzpatrick - 05 Mar 2026 Form 4 Insider Report for Sionna Therapeutics, Inc. (SION)

Role
Chief Legal Officer
Signature
Jennifer Fitzpatrick
Issuer symbol
SION
Transactions as of
05 Mar 2026
Net transactions value
-$347,019
Form type
4
Filing time
06 Mar 2026, 18:56:05 UTC
Previous filing
06 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Fitzpatrick Jennifer Chief Legal Officer C/O SIONNA THERAPEUTICS, INC., 21 HICKORY DRIVE, SUITE 500, WALTHAM Jennifer Fitzpatrick 06 Mar 2026 0002061851

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SION Common Stock Options Exercise +10,250 $6.11* 10,250 05 Mar 2026 Direct F1
transaction SION Common Stock Sale $347,019 -10,250 -100% $33.86 0 05 Mar 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SION Non-Qualified Stock Option (right to buy) Options Exercise -10,250 -17% $0.000000* 50,935 05 Mar 2026 Common Stock 10,250 $6.11 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2025.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.56 to $34.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3 25% of the shares underlying this option vested on June 3, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.